Use of bisphosphonates in patients with metastatic bone disease.
Tumor-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by products produced by tumors or indirectly through other nonmalignant cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Since these agents had demonstrated efficacy in treating other diseases associated with increased bone resorption, including cancer-related hypercalcemia and Paget's disease of bone, studies were initiated to explore the use of bisphosphonates in patients with osteolytic bone metastases. Recent, large, randomized, double-blind studies have shown the efficacy of these agents in reducing skeletal complications in patients with bone metastases from both breast cancer and multiple myeloma.
Berenson
J R
JR
West Los Angeles VA Medical Center, California, USA.
Lipton
A
A
D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D001862:Bone Resorption / Q000188:drug therapy; D001943:Breast Neoplasms / Q000473:pathology; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000473:pathology
D004164:Diphosphonates